Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963064 · ClinicalTrials.gov registry record · Phase 1
JSP191 Antibody Targeting Conditioning in SCID Patients
A Phase 1 study, sponsored by Jasper Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02963064: Clinical Trial Phase 1 study, sponsored by Jasper Therapeutics.
NCT02963064 is a Phase 1 study that was terminated before completion, run by Jasper Therapeutics. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963064, a Phase 1 study, was terminated before completion, sponsored by Jasper Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
Primary Outcome
The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.
Interventions
- BIOLOGICAL Humanized anti-CD117 Monoclonal Antibody (JSP191)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2025-07-07 |
| Phase | Phase 1 |
Why NCT02963064 stopped before completion
NCT02963064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Humanized anti-CD117 Monoclonal Antibody (JSP191) is the first listed.
NCT02963064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02963064 about?
NCT02963064 is a clinical study titled "JSP191 Antibody Targeting Conditioning in SCID Patients". A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
What is the current status of trial NCT02963064?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2017-03-20. Estimated completion is 2025-07-07.
What interventions are being tested in trial NCT02963064?
The interventions under investigation include: Humanized anti-CD117 Monoclonal Antibody (JSP191) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02963064?
This trial is sponsored by Jasper Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02963064's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI